JB Chemicals & Pharmaceuticals is currently trading at Rs. 365.50, up by 0.95 points or 0.26% from its previous closing of Rs. 364.55 on the BSE.
The scrip opened at Rs. 361.60 and has touched a high and low of Rs. 365.50 and Rs. 361.60 respectively.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 407.10 on 28-May-2019 and a 52 week low of Rs. 236.00 on 11-Jul-2018.
Last one week high and low of the scrip stood at Rs. 385.00 and Rs. 361.60 respectively. The current market cap of the company is Rs. 2932.65 crore.
The promoters holding in the company stood at 56.02%, while Institutions and Non-Institutions held 21.16% and 22.82% respectively.
The US Food and Drug Administration (USFDA) has concluded inspection of JB Chemicals & Pharmaceuticals’ newly set up and commissioned solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat.
At the end of inspection, no objectionable observations were found and hence no Form 483 was issued. The said inspection was carried out from June 24, 2019 to June 28, 2019. This facility has capacity of 2 billion tablets per annum, which is expandable to 9 billion tablets per annum.
This new facility has already been approved by EU authorities in February 2019 and classified as cGMP compliant. The new facility will augment the company's manufacturing capacity for regulated markets like USA and EU as and when the product approvals are received.
JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: